Scientists find a ‘kill switch’ in the body that can destroy cancer cells

Each advancement in cancer research brings renewed hope to millions battling this devastating disease.

Scientists at the UC Davis Comprehensive Cancer Center in Sacramento, California, have introduced a promising new approach to cancer treatment. Their findings, published in the journal Cell Death & Differentiation, highlight a breakthrough in targeting cancer cells.

Their research focuses on CD95 receptors, also known as Fas or “death receptors,” which trigger cancer cells to self-destruct. “Previous attempts to target this receptor have failed. However, now that we’ve identified this epitope (target), we may have a viable therapeutic strategy for addressing Fas in tumors,” explained Jogender Tushir-Singh, senior author of the study and associate professor in the Department of Medical Microbiology and Immunology.

These CD95 receptors are found on the surface of cells and, when activated, initiate molecular processes leading to cell destruction. While they are crucial for maintaining cellular balance, their full potential has remained largely unexplored until now.

One of the greatest challenges in cancer treatment is therapeutic resistance, where cancer cells adapt and become unresponsive to conventional therapies. Currently, standard treatments include surgery, chemotherapy, and radiotherapy. Additionally, immune-based therapies such as CAR (chimeric antigen receptor) T-cell therapy have been introduced, but their success has been limited to specific cancer types.

“Although CAR T-cell therapies have shown promise in treating blood cancers like leukemia, achieving long-term remission remains a major hurdle,” Tushir-Singh told Fox News.

The study suggests that this new discovery could significantly improve the effectiveness of CAR-T therapies, expanding their potential beyond leukemia to solid tumors.

By targeting the Fas epitope, researchers hope to prevent cancer cells from evading treatment by inducing programmed cell death. This approach could not only help overcome therapeutic resistance but also enhance the effectiveness of existing immunotherapies.

“The success of CAR-T therapy depends on off-target killing through Fas,” Tushir-Singh told Fox News Digital. He further emphasized the importance of screening cancer patients for Fas expression before undergoing CAR-T therapy to determine its potential effectiveness.

Related Posts

Donald Trump puzzles supporters with call for donations to “get him into heaven.”

Donald Trump Asks Supporters to Donate to ‘Get to Heaven’ — Social Media Reacts The Fundraising Blitz President Donald Trump has asked his MAGA supporters to join…

Coconut Custard Pie

If your palate yearns for a confection that unites the velvety opulence of custard with the sun-drenched sweetness of coconut, this Coconut Custard Pie will quell that…

A Nation on Edge: Why Trump’s Approval Rating Just Hit…

A Nation on Edge: Why Trump’s Approval Rating Just Hit Its Lowest Point Yet he mood across the United States is growing increasingly uneasy. The numbers on…

Farmer Stumbles Upon $600 Million Treasure – What He Found Will Leave You Speechless

In a quiet rural town, one farmer’s ordinary day turned into the discovery of a lifetime. While tending to his land, he unearthed something that would make…

I Thought I Was Just Helping A Stranger… Then She Said My Name Like She’d Known Me Forever

It started as just another routine moment. I was on my lunch break, patrolling my usual route, when I saw her—frail, cane in hand, hesitating at the…

The House Was Empty For Years… Until That Old Chevy Showed Up Out Of Nowhere

Everyone said the place was abandoned. Paint peeling, weeds swallowing the porch, windows boarded up since I was a kid. No one had lived there since the…